Outcomes of Post-Transplant Rh-GCSF and Decitabine Maintenance Therapy in Patients With High-Risk Myeloid Neoplasm.
作者信息
Palmer Mathias, Baranwal Anmol, Basmaci Rami, Hassan Khalil, Kutzke Jade, Bartoo Gabriel, Murthy Hemant, Foran James, Mangaonkar Abhishek A, Hefazi Mehrdad, Matin Aasiya, Hogan William J, Litzow Mark, Shah Mithun Vinod, Alkhateeb Hassan B
机构信息
Division of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
Am J Hematol. 2025 Oct;100(10):1891-1894. doi: 10.1002/ajh.70018. Epub 2025 Jul 29.
Abstract
摘要
相似文献
1
Outcomes of Post-Transplant Rh-GCSF and Decitabine Maintenance Therapy in Patients With High-Risk Myeloid Neoplasm.高危骨髓肿瘤患者移植后重组人粒细胞集落刺激因子和地西他滨维持治疗的疗效
Am J Hematol. 2025 Oct;100(10):1891-1894. doi: 10.1002/ajh.70018. Epub 2025 Jul 29.
2
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.口服地西他滨联合西扎苷在极高危急性髓系白血病或骨髓增生异常综合征造血干细胞移植后的维持治疗（GFM-DACORAL-DLI）：一项多中心、单臂、2期试验
Lancet Haematol. 2025 Sep;12(9):e705-e716. doi: 10.1016/S2352-3026(25)00172-3. Epub 2025 Aug 7.
3
Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.芦可替尼与地西他滨联合白消安-环磷酰胺预处理方案用于高危急性髓系白血病或骨髓增生异常综合征患者的复发预防
Front Immunol. 2025 Aug 18;16:1586512. doi: 10.3389/fimmu.2025.1586512. eCollection 2025.
4
[Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].含地西他滨方案的异基因造血干细胞移植治疗骨髓增生异常综合征及骨髓增生异常综合征转化的急性髓系白血病的疗效与安全性
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Apr;31(2):522-531. doi: 10.19746/j.cnki.issn.1009-2137.2023.02.031.
5
Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada.美国和加拿大接受异基因造血细胞移植的 FLT3-ITD 急性髓系白血病成人的临床结局和治疗模式。
Transplant Cell Ther. 2024 Jul;30(7):683.e1-683.e13. doi: 10.1016/j.jtct.2024.04.016. Epub 2024 Apr 23.
6
Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial.地西他滨联合减低强度预处理方案用于接受异基因造血干细胞移植的复合完全缓解的老年急性髓系白血病患者：一项多中心、单臂、2期试验。
Lancet Reg Health West Pac. 2025 Aug 12;61:101664. doi: 10.1016/j.lanwpc.2025.101664. eCollection 2025 Aug.
7
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission.REGAL研究：galinpepimut-S与最佳可用疗法作为急性髓系白血病第二次缓解期维持治疗的比较。
Future Oncol. 2025 Jan;21(1):73-81. doi: 10.1080/14796694.2024.2433935. Epub 2024 Nov 28.
8
Impact of FLT3 inhibitors on the outcomes of FLT3-ITD mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysis.FLT3抑制剂对异基因造血干细胞移植后FLT3-ITD突变急性髓系白血病预后的影响：一项系统评价和荟萃分析。
Leuk Res. 2025 Aug;155:107724. doi: 10.1016/j.leukres.2025.107724. Epub 2025 Jun 2.
9
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.一项针对年龄≥60岁的未经治疗的急性髓系白血病患者，使用TP-0903和地西他滨靶向突变型TP53和/或复杂核型的1b/2期研究。
Cancer Res Commun. 2025 Jul 1;5(7):1129-1139. doi: 10.1158/2767-9764.CRC-25-0091.
10
Impact of Decitabine Conditioning on Allo-HSCT Outcomes in AML and Intermediate-to-High-Risk MDS Patients in Remission.地西他滨预处理对处于缓解期的急性髓系白血病及中高危骨髓增生异常综合征患者异基因造血干细胞移植结局的影响
Cancer Med. 2025 Jul;14(14):e71081. doi: 10.1002/cam4.71081.
本文引用的文献
1
The use of prognostic models in allogeneic transplants: a perspective guide for clinicians and investigators.预测模型在异基因移植中的应用：临床医生和研究人员的视角指南。
Blood. 2023 May 4;141(18):2173-2186. doi: 10.1182/blood.2022017999.
2
Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.急性髓系白血病和骨髓增生异常综合征患者接受异基因造血细胞移植后的结局差异。
Leuk Lymphoma. 2021 Dec;62(14):3411-3419. doi: 10.1080/10428194.2021.1961242. Epub 2021 Aug 4.
3
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.rhG-CSF 联合地西他滨预防高危 MRD 阴性 AML 患者 HSCT 后复发的疗效：一项开放标签、多中心、随机对照试验。
J Clin Oncol. 2020 Dec 20;38(36):4249-4259. doi: 10.1200/JCO.19.03277. Epub 2020 Oct 27.
4
Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.地西他滨在增殖条件下对自然杀伤细胞活力、表型和功能具有双相作用。
Mol Immunol. 2013 Jul;54(3-4):296-301. doi: 10.1016/j.molimm.2012.12.012. Epub 2013 Jan 16.
5
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.首次完全缓解的急性髓系白血病患者的异基因干细胞移植：前瞻性临床试验的系统评价和荟萃分析
JAMA. 2009 Jun 10;301(22):2349-61. doi: 10.1001/jama.2009.813.
Zotero 插件